Ástralía - enska - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - selexipag, quantity: 1200 microgram - tablet, film coated - excipient ingredients: titanium dioxide; hyprolose; maize starch; propylene glycol; iron oxide red; mannitol; hypromellose; magnesium stearate; carnauba wax; iron oxide black - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - selexipag, quantity: 1000 microgram - tablet, film coated - excipient ingredients: mannitol; hypromellose; titanium dioxide; maize starch; hyprolose; magnesium stearate; propylene glycol; iron oxide red; carnauba wax; iron oxide yellow - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - selexipag, quantity: 200 microgram - tablet, film coated - excipient ingredients: iron oxide yellow; carnauba wax; maize starch; magnesium stearate; hyprolose; propylene glycol; mannitol; titanium dioxide; hypromellose - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - selexipag, quantity: 400 microgram - tablet, film coated - excipient ingredients: hyprolose; hypromellose; carnauba wax; magnesium stearate; mannitol; maize starch; propylene glycol; titanium dioxide; iron oxide red - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - selexipag, quantity: 600 microgram - tablet, film coated - excipient ingredients: iron oxide red; hyprolose; carnauba wax; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; mannitol; maize starch; iron oxide black - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - finasteride, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; microcrystalline cellulose; sodium starch glycollate type a; magnesium stearate; docusate sodium; titanium dioxide; hypromellose; indigo carmine aluminium lake; macrogol 400 - treatment of patients with symptomatic benign prostatic hyperplasia (bph) with an enlarged prostate.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate, quantity: 28.1 mg (equivalent: sildenafil, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; hypromellose; calcium hydrogen phosphate; croscarmellose sodium; titanium dioxide; lactose monohydrate; triacetin - used to treat patients with pulmonary arterial hypertension classified as who functional classes ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. the efficacy of sildenafil citrate 20 mg has not been evaluated in patients currently on bosentan therapy.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - montelukast sodium, quantity: 10.4 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; macrogol 6000; iron oxide yellow; hypromellose; titanium dioxide; hyprolose; magnesium stearate; iron oxide red; lactose monohydrate; microcrystalline cellulose - -prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. ,-symptomatic treatment of seasonal allergic rhinitis.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - deferasirox, quantity: 360 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; colloidal anhydrous silica; poloxamer; hypromellose; titanium dioxide; macrogol 4000; purified talc; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. jadenu is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. jadenu is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - deferasirox, quantity: 180 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; colloidal anhydrous silica; poloxamer; hypromellose; titanium dioxide; macrogol 4000; purified talc; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. jadenu is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. jadenu is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.